Pulmonary arterial hypertension (PAH) is a rare disorder characterized by progressive
obliteration of small pulmonary arteries that leads to elevated pulmonary arterial pressure …

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized
by a persistent elevation of pulmonary artery pressure accompanied by right ventricular …

Introduction: Erectile dysfunction (ED) is a highly prevalent condition affecting nearly one in
five men worldwide. The advent of phosphodiesterase type 5 inhibitors (PDE5i) has …

Background Sexual problems are widespread and adversely affect the interpersonal
relationships and the quality of life. Currently, synthetic drugs improving sexual function are …

Aging is one of the risk factors involved in the development of erectile dysfunction (ED).
Growing evidence suggests that oxidative stress is the critical mediator of changes in …

Abstract Hyperglycemia significantly decreases 3′, 5′-cyclic guanosine monophosphate
(cGMP)-dependent pathway activity in the kidney. A well-characterized downstream …

Erectile dysfunction (ED) is defined as the inability to achieve and/or maintain penile
erection sufficient for satisfactory sexual relations, and aging is one of the main risk factors …

To date, benign diseases of the male and female lower urinary and genital tract, such as
erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to …

Avanafil (AVA) is a second-generation phosphodiesterase-5 (PDE5) inhibitor. AVA shows
high selectivity to penile tissues and fast absorption, but has a bioavailability of about 36 …

Erectile dysfunction (ED) is a neurovascular phenomenon modulated by hormonal, local
biochemical, and biomechanical/structural factors of the penis. The success of the orally …